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ABSTRACT
Background: Glioma accounts for the majority of primary malignant brain tumors 
in adults.
Methods: Glioma specimens and normal brain tissues were analyzed for the 
expression levels of GSK-3β and p-GSK-3β (Ser9) by tissue microarray analysis (TMA) 
and Western blotting. Glioma cells over-expressing GSK-3β were used to analyze 
biological functions both in vitro and in vivo.
Results: The levels of p-GSK-3β (Ser9), but not total GSK-3β, are significantly 
up-regulated in glioma tissues compared to normal tissues, and are significantly 
correlated with the glioma grades. Ectopic expression of GSK-3β decreased the 
phosphorylation levels of mTOR and p70S6K1; and inhibited β-catenin, HIF-1α and 
VEGF expression. Forced expression of GSK-3β in glioma cells significantly inhibited 
both tumor growth and angiogenesis in vivo.
Conclusions: These results reveal that GSK-3β regulates mTOR/p70S6K1 
signaling pathway and inhibits glioma progression in vivo; its inactivation via p-GSK-
3β (Ser9) is associated with glioma development, which is new mechanism that may 
be helpful in developing GSK-3β-based treatment of glioma in the future.
INTRODUCTION
Gliomas are the most aggressive types of primary 
intracranial tumors and constitute almost 80% of 
primary brain tumors. In the last 5 years, despite with 
the improvement of some treatments, such as aggressive 
surgery, radiation and chemotherapies, the median 
survival (MS) rate of patients with malignant glioma 
only improved from 10 to 14 months after diagnosis 
[1, 2]. One of the special characters of glioma is well-
perfused blood vessel with very high density in the 
brain, which is different from many other types of 
cancers. Angiogenesis is the formation of new blood 
vessels out of the pre-existing vasculature, and is vital 
for tumorigenesis and tumor development [3]. Glioma 
usually manifests itself as a focal lesion with central 
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necrosis surrounded by an angiogenic tumor rim (one of 
the characteristics of GBM); this type of tumor invades 
the surrounding extracellular matrix, using both white 
matter tracts and blood vessels as substrates. Extensive 
studies have confirmed that angiogenesis is required for 
malignant glioma growth [4, 5].
GSK-3 is a multifunctional Ser/Thr kinase, 
which was first identified as a critical mediator in 
glycogen metabolism and insulin signaling [6, 7]. It is 
now known that GSK-3 is an important component of 
diverse signaling pathways involved in the regulation 
of protein synthesis, glycogen metabolism, cell 
mobility, proliferation and survival [8, 9]. There are 
two mammalian GSK-3 isoforms encoded by distinct 
genes: GSK-3a and GSK-3β, which share 85% identity 
[10]. Despite a high degree of similarity and functional 
overlap, these isoforms are not functionally identical and 
redundant. It is now known that GSK-3β plays a central 
role in a variety of signaling pathways, such as the 
Wnt/β-catenin, Hedgehog, Notch and insulin signaling 
pathways [11–15]. Accordingly, GSK-3β activity 
depends on the balance of phosphorylation levels at 
activating Tyr216 site and inactivating Ser9 site levels. 
A number of kinases can phosphorylate its N-terminal 
serine-9 residue, including AKT and mitogen-activated 
protein kinase (MAPK)-1, leading to the auto-inhibition 
of GSK-3β. The dysregulation of GSK-3β has also been 
implicated in tumorigenesis and cancer progression [8, 
11, 16–18]. However, the role of GSK-3β and GSK-3β 
Ser9 phosphorylation in glioma development is unclear, 
and the mechanisms underlying GSK-3β regulation 
of neoplastic transformation and tumor development 
remains to be elucidated.
In this study, we applied tissue microarray technique 
to detect a significant increase of p-GSK3β-Ser-9 levels 
in most glioma tissues, which is associated with patients 
with high-grade gliomas and metastatic tumors. Moreover, 
overexpression of GSK-3β inhibited angiogenesis and 
tumor growth in vivo. These studies elucidate the specific 
role of GSK-3β in glioma, and helped further determine 
the underlying mechanism of GSK-3β in regulating 
glioma development.
RESULTS
Increase of GSK-3β phosphorylation levels at 
Serine 9 in glioma tissues
The expression levels of GSK-3β and p-GSK-
3β (Ser9) in 9 normal tissue specimens and 90 glioma 
tissues of paraffin-embedded formalin-fixed were 
detected by Tissue Microarray Analysis (TMA). The 
results showed that the expression levels of p-GSK-
3β (Ser9) are significantly up-regulated in glioma 
tissues compared with normal tissues (Figure 1A). The 
relative expression levels of GSK-3β and p-GSK-3β 
(Ser9) were analyzed by two experienced pathologists 
in a blind manner and marked as final IHC scores: 0 
(negative), + (weak), ++ (moderate) and +++ (strong). 
Types of tissues used are listed in Table 1. Higher 
p-GSK-3β (Ser9) expression levels were detected in 
60 (67%) of 90 glioma cases, and were significantly 
correlated with higher glioma grade (Figure 1B). There 
was no significant correlation between total expression 
levels of GSK-3β with the glioma grade and normal 
tissue specimens (Figure 1B). We further analyzed the 
expression levels of GSK-3β and p-GSK-3β (Ser9) in 
5 normal brain tissues and 33 glioma specimens by 
Western blotting assay. Pathologic features of tissue 
samples are listed in Table 2. Consistent with the 
results in TMA, the expression levels of p-GSK-3β 
(Ser9), but not total GSK-3β, were greatly increased 
in glioma tissues, and were positively correlated with 
higher glioma grades (Figure 1C, and 1E). Since GSK-
3β is the initiation step of proteasome-dependent 
degradation of β-catenin, we also examined levels of 
β-catenin in glioma tissues. As shown in Figure 1C and 
1F, the levels of β-catenin expression in glioma tissues 
were significantly increased compared with normal 
tissues, and higher grades of glioma are associated with 
higher expression levels of β-catenin. These results 
indicated that p-GSK-3β (Ser9) plays an important role 
in increasing β-catenin expression and is a potential 
biomarker of glioma development.
GSK-3β inhibits β-catenin and mTOR/p70S6K1 
signal pathways, and down-regulates HIF-1 and 
VEGF expression
To understand the mechanism of GSK-3β in 
regulating glioma development, human glioma cell lines 
U87 and U251 were infected with the adenovirus carrying 
GSK-3β cDNA (Ad-GSK-3β) or GFP control (Ad-GFP). 
The expression levels of GSK-3β were analyzed in these 
cell lines U87-GFP, U87-GSK-3β, U251-GFP, U251-
GSK-3β by Western blotting. As shown in Figure 2A and 
2B, expression levels of GSK-3β were similar in mock 
cells and GFP cells, whereas GSK-3β levels were greatly 
increased in GSK-3β-overexpressing U87 and U251 cells. 
This result demonstrated that these adenovirus infected 
cells successfully overexpress GSK-3β. To identify 
signaling pathways that may be regulated by GSK-3β, 
we demonstrate that delivery of exogenous GSK-3β 
attenuated the expression levels of β-catenin (Figure 
2A and 2B) and decreased the phosphorylation levels of 
mTOR and p70S6K1 (Figure 2C and 2D). No significant 
differences were found in the levels of total mTOR and 
p70S6K1 in any of the cells. MTOR/p70S6K1 signaling 
pathway is known to be involved in regulation of HIF-1α 
stability [21]. Overexpression of GSK-3β is sufficient to 
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Figure 1: Human glioma tissues express high levels of p-GSK-3β (Ser9). A. The expression levels of GSK-3β and p-GSK-3β 
(Ser9) in normal brain tissues and four (I, II, III, IV) grades of glioma tissues were analyzed by human tissue mircroarry, bar 40 μm. B. 
Relative expression levels of GSK-3β and p-GSK-3β (Ser9) in human normal brain tissues and four grades of glioma tissues were analyzed 
by two experienced pathologists in a blind manner and marked as final IHC scores; P value represents the difference of GSK-3β and 
p-GSK-3β (Ser9) expression levels between normal brain tissues and four grades of gliomas sections. (Continued)
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decrease HIF-1α level (Figure 2E). It was reported that 
VEGF is regulated by HIF-1α through hypoxia responsive 
element [22]. Here we demonstrate that GSK-3β 
inhibits VEGF mRNA and protein levels by RT-PCR 
and ELISA assay (Figure 2F and 2G). These results 
showed that ectopic expression of GSK-3β decreased the 
phosphorylation of mTOR and p70S6K1; and inhibited 
β-catenin, HIF-1α and VEGF expression.
Figure 1: (Continued) Human glioma tissues express high levels of p-GSK-3β (Ser9). C. Levels of GSK-3β, p-GSK-3β 
(Ser9) and β-catenin in human normal brain tissues and four grade gliomas tissues were determined by Western blotting; 20 μg of 
protein extracts from U87 cells was used, and β-tubulin was used as an internal loading control. D, E. and F. Relative densities were 
quantified using ImageJ software. Results are presented as mean ± SD from three duplicates. Asterisk indicates significant difference 
when compared to the control (P < 0.05).
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GSK-3β inhibits tumor angiogenesis in vivo
HIF-1α/VEGF pathway is a major angiogenesis 
signaling pathway in both physiological and pathological 
processes [23]. To examine the potential roles of GSK-
3β in angiogenesis, we performed angiogenesis assay 
in vivo. U87-GSK-3β cells were trapped in growth factor-
free Matrigel, and implanted into both flanks of nude 
mice. Uninfected and U87-GFP cells were used as the 
negative control. U87 cells induced angiogenesis, which 
was inhibited by GSK-3β-overexpression (Figure 3A). 
The hemoglobin levels in the plugs were used to evaluate 
angiogenesis responses. Ectopic expression of GSK-3β 
decreased hemoglobin levels by 35% compared to the 
GFP group (Figure 3B). These results demonstrate that 
GSK-3β inhibit tumor-induced angiogenesis.
GSK-3β expression suppresses tumor growth 
in vivo
Angiogenesis is required for tumor growth and 
metastasis. To further determine whether GSK-3β activation 
in U87 is sufficient in inhibiting tumor growth, we generated 
xenograft tumors by the injection of U87-GSK-3β or U87-
GFP control cells subcutaneously into nude mice for 35 
days. As shown in Figure 4A, the sizes of tumors from GSK-
3β-expressing cells were much smaller than those from the 
GFP control group after 5 weeks of the injection. GSK-3β 
overexpression decreased tumor growth by 65% compared to 
the Ad-GFP group (Figure 4B). Then, representative sections 
of the tumors were stained using monoclonal antibody against 
CD31. Consistent with the results in angiogenesis assay, the 
immunohistochemical analysis indicated that there were a 
Table 1 and 2: The information of human brain tissues (types and WHO criteria) was summarized 
in Table I and II
I
Type of tissues WHO grade Number of cases
Normal brain tissue 9
Pilocytic astrocytoma I 18
Diffuse astrocytoma II 9
Oligoastrocytoma II 15
Oligodendroglioma II 11
Anaplastic gliomas 21
Anaplastic astrocytoma III 7
Anaplastic oligoastrocytoma III 7
Anaplastic oligodendroglioma III 7
Glioblastoma multiforme IV 16
II
Type of tissues WHO grade Number of cases
Normal brain tissue 5
Low-grade gliomas 6
Pilocytic astrocytoma I 2
Diffuse astrocytoma II 1
Oligoastrocytoma II 2
Oligodendroglioma II 1
Anaplastic gliomas 5
Anaplastic astrocytoma III 2
Anaplastic oligoastrocytoma III 2
Anaplastic oligodendroglioma III 1
Glioblastoma multiforme IV 6
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Figure 2: Overexpression of GSK-3β attenuated β-catenin and mTOR/p70S6K1 activation in human glioma cells.  
A. U87 and U251 cells were transfected with or without adenovirus carrying GSK-3β or GFP at 10 MOI. After transfection for 48 h, 
the expression levels of GSK-3β, β-catenin and GAPDH were detected by immunoblotting. B. Relative densities were quantified using 
ImageJ software. Asterisk indicates significant difference when compared to the GFP group (P < 0.05). C. Cells transfected with or without 
adenovirus carrying GSK-3β or GFP were subjected to Western blotting analysis for mTOR, p-mTOR, p70S6K1, p-p70S6K1, HIF-1α and 
GAPDH expression. The protein levels from three independent experiments are quantified and presented as mean ± SD. Asterisk indicates 
significant difference when compared to the control (P < 0.05). (Continued)
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Figure 2: (Continued) Overexpression of GSK-3β attenuated β-catenin and mTOR/p70S6K1 activation in human 
glioma cells. D. and E. Cells transfected with or without adenovirus carrying GSK-3β or GFP were subjected to Western blotting analysis 
for mTOR, p-mTOR, p70S6K1, p-p70S6K1, HIF-1α and GAPDH expression. The protein levels from three independent experiments are 
quantified and presented as mean ± SD. Asterisk indicates significant difference when compared to the control (P < 0.05). (Continued)
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rare numbers of CD31-positive microvessels from GSK-
3β-expressing group compared with GFP control group, 
revealing that GSK-3β overexpression significantly reduced 
the formation of tumor microvessels (Figure 4C and 4D). We 
also analyzed GSK-3β, p-mTOR, p-p70S6K1 and HIF-1α 
expression levels by Western blotting in xenograft tumors 
from three groups. As expected, the higher levels of GSK-3β 
expression in the xenograft tumors from U87-GSK-3β cells 
were correlated with the lower expression levels of p-mTOR, 
p-p70S6K1, and HIF-1α (Figure 4E). Similarly, it was 
confirmed that VEGF mRNA expression in xenograft tumors 
were significantly decreased by GSK-3β overexpression 
(Figure 4F). In summary, these results demonstrate that GSK-
3β overexpression inhibits tumor growth.
DISCUSSION
Gliomas are the most common primary brain tumor. 
Despite aggressive treatment approaches, glioma is still 
hardly curable [1, 2]. Extensive studies have demonstrated 
that human glioma exhibits aberrant expression profiles 
of Wnt/beta-catenin signaling [24, 25]. GSK-3β is an 
important molecule to regulate Wnt/beta-catenin signaling, 
and is a key regulator of tumor development [26, 27]. For 
example, GSK-3β has been shown to regulate the JNK 
pathway, and its inhibition triggers apoptosis in pancreatic 
cancer [16]. In bladder cancer, GSK-3β positively 
regulates cell proliferation and survival in vitro [28]. 
To the present, a large number of studies demonstrated 
Figure 2: (Continued) Overexpression of GSK-3β attenuated β-catenin and mTOR/p70S6K1 activation in human 
glioma cells. F. and G. VEGF mRNA and protein levels were detected by semi-quantitative RT-PCR assay and ELISA assay, respectively. 
Asterisks indicate significant difference when compared to the control (P < 0.01).
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GSK-3β as a potential therapeutic target in ovarian, breast 
cancer and bladder cancer [29, 30]. However, the role 
and the molecular mechanism of GSK-3β in glioma still 
remain to be elucidated.
In order to get an insight into the biological relevance 
of GSK-3β in glioma, we did immunohistochemical 
stainings and Western blotting analysis of total GSK-3β 
and phospho-GSK3β at Ser-9 levels in glioma tissues. 
Our study shows that there is a strong expression of total 
GSK-3β in the vast majority of normal and glioma tissues. 
However, the expression levels of p-GSK-3β (Ser9) were 
much higher in glioma tissues when compared to normal 
tissues, and were correlated with higher glioma grades. 
These results suggest that the expression levels of phospho-
GSK-3β-Ser-9 may serve as a valuable prognostic marker 
in glioma. To explore the functional relevance of GSK-3β 
in glioma, we utilized U87 cells infected with adenovirues 
carrying GSK-3β (Ad-GSK-3β). The functional analysis 
Figure 3: Overexpression of GSK-3β inhibited tumor angiogenesis in vivo. A. U87 cells were transfected with or without 
adenovirus carrying GSK-3β or GFP at 10 MOI. After the cells were cultured for 48 h, aliquots of cells (1.0 × 106 cells, 0.1ml) were mixed 
in 1:2 ratio with growth factor-reduced phenol red-free Matrigel, and injected subcutaneously into both flanks of nude mice. After 12 
days of implantation, the representative plugs from each group were shown. Scale bar: 5 mm. B. The hemoglobin levels in plugs (n = 10).  
* indicates significant difference when compared to that of the GFP group (P < 0.05).
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Figure 4: Overexpression of GSK-3β decreased tumor growth in vivo. A. U87 cells were transfected with or without adenovirus 
carrying GSK-3β or GFP at 20 MOI. After the cells were cultured for 48 h, 3 × 106 cells were injected into both flanks of nude mice. Representative 
tumors 35 days after implantation from each group were shown. (Bar: 5 mm) B. The tumor weight was measured for each xenograft. Asterisks 
indicate significant difference when compared to the GFP group (P < 0.05). C. Representative image of CD31-stained sections. (Continued)
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Figure 4: (Continued) Overexpression of GSK-3β decreased tumor growth in vivo. D. Quantitative analysis of MVD in the 
xenograft plugs sections. The graph represents the mean ± SD from five different tumor sections for each group. *indicated significant 
difference at p < 0.05. E. The protein levels of mTOR, p-mTOR, p70S6K1, p-p70S6K1 and HIF-1α in tumor tissues were analyzed by 
Western blotting. GAPDH was used as internal control. (Continued)
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reveals that ectopic expression of GSK-3β suppressed 
angiogenesis and tumor growth in vivo.
It is reported that GSK3β is able to phosphorylate 
β-catenin, thus marking the protein for degradation [27, 
31]. The expression levels of β-catenin were higher in 
glioma tissues compared to the normal tissues, and were 
decreased following ectopic expression of GSK-3β in U87 
and U251 cells. Therefore, the Wnt/β-catenin signaling 
pathway may be involved in the process of glioma 
development. Moreover, in the present study, changes in 
mTOR/p70S6K1 signaling pathway occurred in U87 and 
U251 glioma cells following GSK-3β overexpression, 
suggesting that this signaling pathway may play 
an important role in the GSK-3β-inhibited glioma 
development events. It is currently unknown whether there 
is cross-talk between the β-catenin and mTOR cascades 
in this regard or if they work independently to strengthen 
development. Further investigations are needed to reveal 
resolve the relationship between these two signaling 
pathways in the context of GSK-3β-inhibited glioma 
development.
The mTOR/p70S6k1 signaling pathway is known 
to be involved in regulation of HIF-1α stability [32]. 
VEGF is a key proangiogenic activator which can be 
induced at transcriptional level by HIF-1α, and well 
known to play an important role in tumor growth and 
angiogenesis. Our previous studies revealed that high 
expression of VEGF defines carcinomas with more tumor 
growth and angiogenesis and poor prognosis. In this study, 
overexpression of GSK-3β dramatically down regulates 
HIF-1α protein expression as well as VEGF mRNA 
levels, Thus, HIF-1α/VEGF pathway may be involved in 
transmitting the biological effects of GSK-3β- inhibited 
tumor growth and angiogenesis.
In conclusion, our current study demonstrates 
that p-GSK-3β (Ser9) levels are positively related with 
higher glioma grades; ectopic expression of GSK-3β is 
sufficient to inhibit angiogenesis and tumor growth; we 
further identify Wnt/β-catenin and mTOR/p70S6K1/HIF-
1a/VEGF pathways are involved in GSK-3β-inhibited 
angiogenesis and tumor growth. Taken together, these 
findings suggest that p-GSK-3β (Ser9) may be a useful 
biomarker for glioma development, and provide new 
information for using GSK-3β-based diagnostics and/or 
potential therapeutic target for glioma treatments in the 
future.
MATERIALS AND METHODS
Cell culture and reagents
Human glioma cell lines U87 and U251 (American 
Type Culture Collection, Manassas, VA, USA) were 
cultured in DMEM supplemented with 2 mmol/L 
l-glutamine, 10% fetal bovine serum, 100 units/mL 
penicillin, and 100 mg/mL streptomycin, 5% CO2 at 37°C. 
Antibodies against GSK-3β, phospho-GSK-3β (Ser9), 
β-catenin, AKT, phospho-AKT (Ser473), p70S6K1, 
phospho-p70S6K1, mTOR, phospho-mTOR, β-Tubulin 
were obtained from Cell Signaling (Beverly, MA, USA). 
HIF-1α was from BD Biosciences (Franklin Lakes, NJ, 
USA), and GAPDH was purchased from KangCheng 
Biotech (Shanghai, China), while antibody against CD31 
was supplied by Abcam (Cambridge, UK).
Figure 4: (Continued) Overexpression of GSK-3β decreased tumor growth in vivo. F. The mRNA levels of VEGF were 
analyzed in tumor tissues by semi-quantitative RT-PCR assay.
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Tissue samples
Tissues were obtained from the first affiliated 
hospital of Nanjing Medical University, Nanjing, China. 
Total 9 human normal brain tissues and 90 human 
glioma tissues were obtained as paraffin-embedded 
formalin-fixed blocks. Fresh 5 normal brain tissues 
and 33 glioma specimens were collected immediately 
after the surgical removal, and snap-frozen in liquid 
nitrogen. All patients were provided written informed 
consent, and the experimental procedures were approved 
by the Institutional Review Board of Nanjing Medical 
University. For all of the cases, the pathological diagnosis 
and grading were confirmed by two experienced 
pathologists in accordance to the principles of World 
Health Organization Classification. Types of tissues used 
are listed in Table I and II.
Tissue microarray and immunohistochemistry
Two separated cores taken from paraffin-embedded 
specimens of 90 glioma cases and 9 normal brain tissues 
were used to construct tissue microarrays. Slides and 
sections of the glioma tissues were stained with GSK-
3β (1:50 dilution) and phospho-GSK-3β (Ser9) (1:100 
dilution) antibodies (Cell Signaling, MA, USA), 
and then detected by EnVision DAB kit from Dako 
(Carpinteria, CA, USA). Staining intensity levels were 
independently scored by two observers. Average staining 
scores were determined for tissue cores of each case. 
Histopathologic diagnosis was examined independently 
by immunohistochemical analysis to reduce bias in 
scoring staining intensity. Staining intensity is graded 
on a 0–3 scales, on which 0 indicated no staining, 1 
indicated weak, 2 indicated moderate, 3 indicated the 
most intense.
Adenovirus preparation and transduction 
efficiency
The GSK-3β cDNA was sub-cloned into pAdtrack-
CMV shuttle vector. The resulting plasmid pAdtrack-
CMV-GSK-3β was linearized with Pme I followed by 
homologous recombination with backbone plasmid 
pAdEasy-1 in BJ5183 cells to generate recombinant 
adenovirus plasmid pAd-GSK-3β (Ad-GSK-3β). The 
DNA of identified Ad-GSK-3β was digested with Pac 
I, and transfected into 293A cells by lipofectamine-
mediated method to package recombinant adenovirus. 
The titre of the Ad-GSK-3β was measured with the 
aid of green fluorescence protein (GFP) expression 
after multiplication and purification. In general, the 
cell infection was dose-dependent in the range of 5–20 
MOI. More than 80% of infected cells were obtained at 
10 MOI for U87 and U251 cells after 72 h; thus cells 
were infected at 10 MOI from the studies as described 
in Figures 2–4.
Immunoblotting
Tissues and cells were lysed on ice for 30 min in 
RIPA buffer (100 mM Tris, 150 mM NaCl, 1% Triton, 1% 
deoxycholic acid, 0.1% SDS, 1 mM EDTA, and 2 mM NaF) 
supplemented with 1 mM sodium vanadate, 2 mM leupeptin, 
2 mM aprotinin, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 mM DTT, and 2 mM pepstatin A. The supernatant 
was collected after centrifugation at 12,000 rpm/min for 15 
min, and protein concentration was determined using protein 
assay reagent from Bio-Rad (Hercules, CA, USA). Proteins 
were electrophoretically separated by SDS-PAGE and 
transferred to nitrocellulose (Trans-Blot Transfer Medium, 
Bio-Rad). Membranes were blocked with 5% nonfat dry 
milk in PBS containing 0.05% Tween 20, and incubated 
with specific antibodies. Protein bands were detected 
by incubation with horse radish peroxidase-conjugated 
antibodies (Cell signaling), and visualized through enhanced 
chemiluminescence reagent (Thermo Fisher).
Reverse transcription–PCR (RT–PCR)
Total RNAs were extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instruction. Two micrograms of total 
RNAs were used for cDNA synthesis using PrimeScript 
RT Master kit (TaKaRa, Dalian, China). Reverse 
transcription-PCR (RT-PCR) analysis was performed 
using the cDNAs as the template. PCR was amplified for 
less than 30 cycles. Levels of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used as the internal control. 
Primers for the PCR analysis were as follows: VEGF, 
5′-TCGGGCCTCCGAAACCATGA-3′ (sense), and 
5′-CCTGGTGAGAGATCTGGTTC-3′ (antisense); and 
GAPDH, 5′-CCACCCATGGCAAATTCCATGGCA-3′ 
(sense) and 5′-TCTAGACGGCAGGTCAGGTCCACC-3′ 
(antisense).
ELISA assay
Capture ELISA was performed using a human 
VEGF ELISA kit according to the manufacturer’s 
instruction (R&D Systems). Optical densities were read at 
405 nm, and the rate of VEGF secretion was calculated as 
previously described [19].
Angiogenesis and tumor growth assay
The 4-week-old male nude mice [BALB/cA-nu 
(nu/nu)] were purchased from Shanghai Experimental 
Animal Center (Chinese Academy of Sciences, China), 
maintained in pathogen-free conditions, and sustained 
with standard diets. All studies were approved by the 
Institutional Committee on Animal Care of Nanjing 
Medical University. For angiogenesis assay in nude male 
mice, animals were randomly divided into two groups 
(n = 5). U87 cells were trypsinized, and suspended in 
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serum-free medium (5 × 107 cells/ml). Aliquots of cells 
(5 × 106 cells) were mixed with 0.2 ml growth factor-
reduced phenolred-free Matrigel (BD Biosciences, MA, 
USA), and injected subcutaneously into both flanks of 
BALB/cA-nude mice. The Matrigel plugs were removed 
from the mice 9 days after the implantation, and surrounding 
tissues were trimmed. The plugs were photographed and 
weighed, and immersed immediately into lysis buffer 
(1 mM EDTA and 5 mM phosphate, pH 8), and incubated 
at 4°C for 24 h. Hemoglobin content levels were measured 
using a Drabkin’s reagent kit (Sigma-Aldrich, St Louis, 
MO) based on the manufacturer’s instruction.
For tumor growth assay, animals were randomly 
divided into two groups (n = 8). A total of 1 × 107 U87 
cells suspended in serum-free DMEM medium were 
transplanted subcutaneously into both flanks of nude mice. 
The mice were euthanized 30 days after the injection, 
the xenograft tumors were removed from the mice and 
analyzed. Tumor tissues were embedded in paraffin, cut 
into 5 μm, and placed sections onto glass slides. Sections 
of tumors were stained with monoclonal antibody against 
CD31, and detected through streptavidin-biotin-horse 
radish peroxidase complex (SABC) formation. The 
relative angiogenesis levels were estimated by micro-
vessel density (MVD) as previously described [20].
Statistical analysis
Statistical analysis was performed using Stata 
statistical package (Version 10.0, Stata Corp, LP, USA). 
Pearson χ2 test or Fisher exact tests were used to compare 
qualitative variables, and the differences are considered 
significance at P < 0.05. The quantitative variables were 
analyzed by the Student t-test.
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